000324931 001__ 324931
000324931 005__ 20230214180622.0
000324931 0247_ $$2CORDIS$$aG:(EU-Grant)731060$$d731060
000324931 0247_ $$2CORDIS$$aG:(EU-Call)H2020-INFRAIA-2016-1$$dH2020-INFRAIA-2016-1
000324931 0247_ $$2originalID$$acorda__h2020::731060
000324931 035__ $$aG:(EU-Grant)731060
000324931 150__ $$aResearch Infrastructures for the control of vector-borne diseases$$y2017-02-01 - 2022-06-30
000324931 371__ $$aLIVERPOOL SCHOOL OF TROPICAL MEDICINE$$dUnited Kingdom$$ehttp://www.liv.ac.uk/lstm/lstm.html$$vCORDIS
000324931 371__ $$aFondation Health Sciences e-Training$$dSwitzerland$$ehttp://hset.bio-med.ch$$vCORDIS
000324931 371__ $$aTROPIQ HEALTH SCIENCES$$dNetherlands$$ehttp://www.tropIQ.nl$$vCORDIS
000324931 371__ $$aUniverzitet u Novom Sadu, Poljoprivredni fakultet Novi Sad$$dSerbia$$ehttp://polj.uns.ac.rs$$vCORDIS
000324931 371__ $$aSTICHTING KATHOLIEKE UNIVERSITEIT$$dNetherlands$$ehttp://www.ru.nl$$vCORDIS
000324931 371__ $$aMax Planck Society$$bMPG$$dGermany$$ehttp://www.mpg.de/en$$vCORDIS
000324931 371__ $$aUniversity of Glasgow$$bUniversity of Glasgow$$dUnited Kingdom$$ehttp://www.gla.ac.uk/$$vCORDIS
000324931 371__ $$aIDRYMA TECHNOLOGIAS KAI EREVNAS$$bFOUNDATION FOR RESEARCH AND TECHNOLOGYHELLAS$$dGreece$$ehttp://www.forth.gr$$vCORDIS
000324931 371__ $$aUniversity of Zurich$$bUZH$$dSwitzerland$$ehttp://www.uzh.ch/index_en.html$$vCORDIS
000324931 371__ $$aEUROPEAN MOLECULAR BIOLOGY LABORATORY$$bEMBL$$dGermany$$ehttp://www.embl.org$$vCORDIS
000324931 371__ $$aInstitut Pasteur de Dakar$$bInstitut Pasteur de Dakar$$dSenegal$$ehttp://www.pasteur.sn/$$vCORDIS
000324931 371__ $$aInstitut Pasteur de Nouvelle Calédonie$$bIPNC$$dNew Caledonia$$ehttps://www.institutpasteur.nc/$$vCORDIS
000324931 371__ $$aMinistère De La Santé$$bMinistère De La Santé$$dBurkina Faso$$ehttp://www.sante.gov.bf/$$vCORDIS
000324931 371__ $$aInstitut Pasteur$$bInstitut Pasteur$$dFrance$$ehttp://www.pasteur.fr/en$$vCORDIS
000324931 371__ $$aPOLO D'INNOVAZIONE DI GENOMICA, GENETICA E BIOLOGIA SCARL$$bPOLOGGB$$dItaly$$ehttp://www.pologgb.com$$vCORDIS
000324931 371__ $$aINSTITUT DE RECERCA I TECNOLOGIA AGROALIMENTARIES$$bINSTITUTE FOR FOOD AND AGRICULTURE RESEARCH AND TECHNOLOGY$$dSpain$$ehttp://www.irta.es$$vCORDIS
000324931 371__ $$aCENTRO AGRICOLTURA E AMBIENTE GIORGIO NICOLI SRL$$bCAA$$dItaly$$ehttp://www.caa.it$$vCORDIS
000324931 371__ $$aImperial College of Science Technology and Medicine$$bImperial$$dUnited Kingdom$$ehttp://www.imperial.ac.uk$$vCORDIS
000324931 371__ $$aCentre de Coopération Internationale en Recherche Agronomique pour le Développement$$bCIRAD$$dFrance$$ehttp://www.cirad.fr/en/home-page$$vCORDIS
000324931 371__ $$aWageningen University$$bWU$$dNetherlands$$ehttp://www.wur.nl/$$vCORDIS
000324931 371__ $$aThe Pirbright Institute$$bTPI$$dUnited Kingdom$$ehttp://www.pirbright.ac.uk$$vCORDIS
000324931 371__ $$aInstitut de Recherche pour le Développement$$bIRD$$dFrance$$ehttps://www.ird.fr/$$vCORDIS
000324931 371__ $$aCharles University$$bCharles University$$dCzechia$$ehttp://www.cuni.cz/UKENG-1.html$$vCORDIS
000324931 371__ $$aUniversité des Sciences, des Techniques et des Technologies de Bamako$$bUSTTB$$dMali$$ehttp://www.usttb.edu.ml/index.php/$$vCORDIS
000324931 372__ $$aH2020-INFRAIA-2016-1$$s2017-02-01$$t2022-06-30
000324931 450__ $$aINFRAVEC2$$wd$$y2017-02-01 - 2022-06-30
000324931 5101_ $$0I:(DE-588b)5098525-5$$2CORDIS$$aEuropean Union
000324931 680__ $$aThe overall objective of the Infravec2 project is to integrate key specialized research facilities necessary for European excellence in insect vector biology, to open the infrastructure for European access, and to develop new vector control measures targeting the greatest threats to human health and animal industries. Infravec2 is an Advanced Community, following a four-year Starting Community lifecycle (FP7 Infravec1). Lack of access to key infrastructures limits European vector research and impedes development of vector control measures. Insect vectors transmit parasitic diseases such as malaria and leishmaniasis, and viral infections such as chikungunya, dengue, Zika, Japanese encephalitis and yellow fever. Vector-borne diseases, which have historically been a problem of tropical countries, now represent a threat for temperate regions of the world including much of Europe. The 24 consortium partners, including 4 commercial companies, hold the major European biosecure insectaries for experimental infection and containment of insect vectors under Containment Level 2 and 3 (CL2/CL3) conditions, other key insect vector facilities, and include front-line field sites in Africa, the Pacific, and the Americas. Infravec2 will implement comparable standards across the secure insectary facilities as a world first, improving exploitation of European vector infrastructures for research and public health, and will develop other innovative methodologies and technologies. Networking activities will assure that the project achieves full impact, producing a step change in European vector biology research and the product pipeline, and consolidating European global leadership in insect vectors. The goal of the Infravec2 project is to build a durable European infrastructure to control insect vector-borne disease, including with power to predict and prevent the inevitable next epidemic outbreak in advance.
000324931 909CO $$ooai:juser.fz-juelich.de:830632$$pauthority$$pauthority:GRANT
000324931 909CO $$ooai:juser.fz-juelich.de:830632
000324931 970__ $$aoai:dnet:corda__h2020::c6056512eac8bcdd1ee8f841a149287e
000324931 980__ $$aG
000324931 980__ $$aCORDIS
000324931 980__ $$aAUTHORITY